Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial

Manuscript Number: 

15-0538R2

Author(s): 
Guosong Liu, Zhong-Lin Lu, Safa Sadeghpour, Jason G. Weinger, Feng Xue

Disclosures

Guosong Liu

  • Equity:
    I am founder of Neurocentria and own some stocks of Neurocentria.
    Sponsors:
    I am CSO of Neurocentria, the company who sponsor the study.
    Patents/Royalties
    I am co-inventor of the patents the lead to development of MMFS-1 used in the current study.

Zhong-Lin Lu

  • Nothing to Disclose

Safa Sadeghpour

  • Consulting Fees:
    Employee of Neurocentria, Inc.
    Equity:
    Hold equity in Neurocentria, Inc.
    Sponsors:
    Employee of Neurocentria, Inc.

Jason G. Weinger

  • Equity:
    As an employee of Neurocentria, I receive a small amount of stock options.
    Sponsors:
    I am the Manager of Scientific Operations, for R&D and drug development

Feng Xue

  • Nothing to Disclose